ArcellxACLX
ACLX
About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Employees: 163
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
165% more call options, than puts
Call options by funds: $51.8M | Put options by funds: $19.6M
17% more funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 14 (+2) [Q1 2025]
2.65% more ownership
Funds ownership: 109.42% [Q4 2024] → 112.07% (+2.65%) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 68
7% less funds holding
Funds holding: 210 [Q4 2024] → 195 (-15) [Q1 2025]
11% less capital invested
Capital invested by funds: $4.54B [Q4 2024] → $4.04B (-$495M) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$93
41%
upside
Avg. target
$93
41%
upside
High target
$93
41%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank George Farmer | 41%upside $93 | Sector Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at.
Neutral
Business Wire
1 month ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
Negative
Zacks Investment Research
1 month ago
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.14 per share a year ago.
Neutral
Business Wire
1 month ago
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. “Delivering therapies that can positively impact patients' lives is our mission,” said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. “We are pleased tha.
Positive
Seeking Alpha
1 month ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Positive
Seeking Alpha
1 month ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Neutral
Business Wire
2 months ago
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare.
Neutral
GlobeNewsWire
2 months ago
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Positive
Seeking Alpha
2 months ago
Arcellx Impressive Safety Data Leaves Doubts
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Negative
Zacks Investment Research
3 months ago
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to earnings of $0.42 per share a year ago.
Charts implemented using Lightweight Charts™